Development of continuous fermentation has been driven by the increased production of monoclonal antibodies says GEA, with Asia-Pacific the new growth driver for such technologies.
Reliance Life Sciences has been contracted to make the first Indian biosimilar of J&J’s Remicade (infliximab), though Epirus Biopharmaceuticals says it is looking to Fujifilm for its European supply.
Genzyme has filed a patent application for a technology platform that will bridge the gap between upstream and downstream processing in continuous biomanufacturing.
CDMO ProBioGen has invested €20m ($26m) in its manufacturing plant in Germany and says it will install two 1,000L single-use bioreactors and employ roughly 75 new staff.
Patheon has acquired Gallus BioPharmaceuticals adding two US biologics plants and says with an industry shift towards medium sized bioreactors it now holds the market advantage.
Japanese biotech company Unigen has implemented in only four months Werum's PAS-X Manufacturing Execution System (MES), which can help optimize production output at the world’s largest plant for the contract manufacturing of recombinant flu vaccines.
Biologic manufacturer PlantForm and PharmaPraxis have established a joint venture to develop, manufacture and commercialize biosimilar versions of six key biopharma treatments.
India is looking to stimulate investment in biotechnology through bioclusters and development of the International Centre for Genetic Engineering and Biotechnology (ICGEB).
Contract manufacturing organisation (CMO) Cobra Biologics is to produce biologics with an increased half-life using a PEGylation platform from biotech QuiaPEG.
CDMO (contract development and manufacturing organization) PacificGMP has doubled its GMP (good manufacturing practice) production capacity with the addition of a second System 1000 bioreactor platform from GE Healthcare.
Biomanufacturing in India is being held back by a lack of skilled workers but training initiatives are helping to address the problem, say Oncobiologics and Biocon.
The biotechnology and pharmaceutical bodies AusBiotech and Medicines Australia have asked the Australian Minister for Industry to invest in biopharma R&D and secure patents.
Biologics makers must think about costs surrounding chronic therapies and continuous processing, says a company making software predicting manufacturing scenarios.
Gallus BioPharmaceuticals has chosen TAP Biosystems, acquired last October by the Sartorius Stedim Biotech Group, to provide single-use bioreactors for its latest facility.
GE Healthcare Life Sciences has signed a licensing agreement for Promosome’s suite of mammalian cell line development technologies, which aim to increase protein expression in mammalian cell culture.
Small-sized Australian biopharma developers will be able to use a GMP cell line contract manufacturing facility operated by Patheon Biologics (formerly DSM Biologics) as a result of a AUS$2m (US$1.8m) grant fund.
Catalent has increased its stake in Redwood Biosciences telling us it is committed to the development of antibody-drug conjugates (ADCs) and the SMARTag technology platform.
In what may be an early indication of states looking to get more involved in biologic development, EMD Millipore has won a $400,000 grant from the Massachusetts Life Sciences Center (MLSC) to fund a partnership with Promethera Biosciences.
The high street of tomorrow is likely to be a mix of supermarkets, banks and biopharmaceutical manufacturing plants according to one expert who says urban drug production has significant advantages for Pharma firms and patients.
Downstream processing techs are harder to use and the focus of less innovation than systems employed upstream says the team developing the UK's new National Biologics Manufacturing Centre.
Thermo Fisher Scientific has confirmed that the price cuts imposed by Chinese M&A authorities are part of the country’s efforts to become and biopharmaceutical hub.
US defence contractor Nanotherapeutics will use a modular biomanufacturing system provided by GE Healthcare at a facility it is building in Alachua, Florida.
Buying ATMI will help Pall fill gaps in its up and downstream biomanufacturing tech offerings but the deal does not rule out other acquisitions says CEO, Larry Kingsley
WuXi PharmaTech has predicted that demand for its biopharmaceutical manufacturing services will increase this year just days after upping its guidance for fiscal 2013.
Cellexus has launched a new bioreactor system that employs an air-based mixing system that is better at aerating cell cultures than rocking or large chamber systems.
Choosing the same biomanufacturing tech supplier for development and commercial systems cuts scale steps and reduces lead times according to Cobra Biologics.
ATMI has started exploring strategic alternatives but insists that its bioreactor business is positioned to benefit from increasing biopharma demand for single-use techs.
Biocatalyst and microbial strain developer Brain AG was recognised for furthering industrial use of biotechnology in a ceremony at the Biotechnica trade show in Hanover, Germany yesterday.
The biopharmaceutical manufacturing sector needs better cross flow filtration technologies according to GE Healthcare, which says that advances in bioreactor systems have not been matched downstream.
Plastic may be greener than stainless steel, but industry still needs to find a more recyclable alternative for biomanufacturing systems according to Greenpeace.
Fujifilm Diosynth Biotechnologies has opened a mammalian cell culture-based manufacturing facility in the UK in the latest stage of an effort to expand its business.
